Search Results - "Stál, O"

Status of the charged Higgs boson in two Higgs doublet models by Arbey, A., Mahmoudi, F., Stål, O., Stefaniak, T.

“…The existence of charged Higgs boson(s) is inevitable in models with two (or more) Higgs doublets. Hence, their discovery would constitute unambiguous evidence…”
Get full text

Dark matter in the inert doublet model after the discovery of a Higgs-like boson at the LHC by Goudelis, A., Herrmann, B., Stål, O.

“…A bstract We examine the Inert Doublet Model in light of the discovery of a Higgs-like boson with a mass of roughly 126 GeV at the LHC. We evaluate one-loop…”
Get full text

Interpreting the LHC Higgs search results in the MSSM by Heinemeyer, S., Stål, O., Weiglein, G.

“…Recent results reported by the ATLAS and CMS experiments on the search for a SM-like Higgs boson both show an excess for a Higgs mass near 125 GeV, which is…”
Get full text

MSSM Higgs boson searches at the LHC: benchmark scenarios after the discovery of a Higgs-like particle by Carena, M., Heinemeyer, S., Stål, O., Wagner, C. E. M., Weiglein, G.

“…A Higgs-like particle with a mass of about 125.5 GeV has been discovered at the LHC. Within the current experimental uncertainties, this new state is…”
Get full text

Defining the human copper proteome and analysis of its expression variation in cancers by Blockhuys, S, Celauro, E, Hildesjö, C, Feizi, A, Stål, O, Fierro-González, J C, Wittung-Stafshede, P

“…Copper (Cu) is essential for living organisms, and acts as a cofactor in many metabolic enzymes. To avoid the toxicity of free Cu, organisms have specific…”
Get full text

MSSM interpretations of the LHC discovery: light or heavy Higgs? by Bechtle, P., Heinemeyer, S., Stål, O., Stefaniak, T., Weiglein, G., Zeune, L.

“…A Higgs-like particle with a mass of about 126 GeV has been discovered at the LHC. Within the experimental uncertainties, the measured properties of this new…”
Get full text

Prospects for charged Higgs searches at the LHC by Akeroyd, A. G., Aoki, M., Arhrib, A., Basso, L., Ginzburg, I. F., Guedes, R., Hernandez-Sanchez, J., Huitu, K., Hurth, T., Kadastik, M., Kanemura, S., Kannike, K., Khater, W., Krawczyk, M., Mahmoudi, F., Moretti, S., Najjari, S., Osland, P., Pruna, G. M., Purmohammadi, M., Racioppi, A., Raidal, M., Santos, R., Sharma, P., Sokołowska, D., Stål, O., Yagyu, K., Yildirim, E.

“…The goal of this report is to summarize the current situation and discuss possible search strategies for charged scalars, in non-supersymmetric extensions of…”
Get full text

Flavor constraints on two-Higgs-doublet models with general diagonal Yukawa couplings by Mahmoudi, F., Stål, O.

“…We consider constraints from flavor physics on two-Higgs-doublet models (2HDM) with general, flavor-diagonal, Yukawa couplings. Analyzing the charged Higgs…”
Get full text

Confronting the MSSM and the NMSSM with the discovery of a signal in the two photon channel at the LHC by Benbrik, R., Gomez Bock, M., Heinemeyer, S., Stål, O., Weiglein, G., Zeune, L.

“…We confront the discovery of a boson decaying into two photons, as reported recently by ATLAS and CMS, with the corresponding predictions in the Minimal…”
Get full text

Improved prediction for the mass of the W boson in the NMSSM by Stål, O., Weiglein, G., Zeune, L.

“…A bstract Electroweak precision observables, being highly sensitive to loop contributions of new physics, provide a powerful tool to test the theory and to…”
Get full text

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial by Jerevall, P-L, Ma, X-J, Li, H, Salunga, R, Kesty, N C, Erlander, M G, Sgroi, D C, Holmlund, B, Skoog, L, Fornander, T, Nordenskjöld, B, Stål, O

“…Background: A dichotomous index combining two gene expression assays, HOXB13 : IL17BR (H : I) and molecular grade index (MGI), was developed to assess risk of…”
Get full text

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer by BOSTNER, J, AHNSTRÖM WALTERSSON, M, FORNANDER, T, SKOOG, L, NORDENSKJÖLD, B, STAL, O

“…The 11q13 region is amplified in approximately 15% of all breast tumors. Situated in this region are the cyclin D1 gene (CCND1) and the p-21-activated kinase 1…”
Get full text

5011 ORAL Assessments of Proliferation in Breast Cancer by Sundquist, M, Holmberg, E, Holmberg, S, Kovacs, A, Mathe, G, Stál, O, Tejler, G, Thorstenson, S

Get full text

Light Higgs bosons in phenomenological NMSSM by Mahmoudi, F., Rathsman, J., Stål, O., Zeune, L.

“…We consider scenarios in the next-to-minimal supersymmetric model (NMSSM) where the CP-odd and charged Higgs bosons are very light. As we demonstrate, these…”
Get full text

Physics at the e+e- linear collider by Moortgat-Pick, G., Baer, H., Battaglia, M., Belanger, G., Fujii, K., Kalinowski, J., Heinemeyer, S., Kiyo, Y., Olive, K., Simon, F., Uwer, P., Wackeroth, D., Zerwas, P. M., Arbey, A., Asano, M., Bagger, J., Bechtle, P., Bharucha, A., Brau, J., Brümmer, F., Choi, S. Y., Denner, A., Desch, K., Dittmaier, S., Ellwanger, U., Englert, C., Freitas, A., Ginzburg, I., Godfrey, S., Greiner, N., Grojean, C., Grünewald, M., Heisig, J., Höcker, A., Kanemura, S., Kawagoe, K., Kogler, R., Krawczyk, M., Kronfeld, A. S., Kroseberg, J., Liebler, S., List, J., Mahmoudi, F., Mambrini, Y., Matsumoto, S., Mnich, J., Mönig, K., Mühlleitner, M. M., Pöschl, R., Porod, W., Porto, S., Rolbiecki, K., Schmitt, M., Serpico, P., Stanitzki, M., Stål, O., Stefaniak, T., Stöckinger, D., Weiglein, G., Wilson, G. W., Zeune, L., Moortgat, F., Xella, S., Ellis, J., Komamiya, S., Peskin, M., Schlatter, D., Wagner, A., Yamamoto, H.

“…A comprehensive review of physics at an e + e - linear collider in the energy range of s = 92  GeV–3 TeV is presented in view of recent and expected LHC…”
Get full text

Activation of AKT PKB in breast cancer predicts a worse outcome among endocrine treated patients by PEREZ-TENORIO, G, STAL, O

“…Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with…”
Get full text

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial by Ekholm, M., Bendahl, P.O., Fernö, M., Nordenskjöld, B., Stål, O., Rydén, L.

“…The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER)–positive…”
Get full text

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial by Johansson, Annelie, Dar, Huma, van 't Veer, Laura J, Tobin, Nicholas P, Perez-Tenorio, Gizeh, Nordenskjöld, Anna, Johansson, Ulla, Hartman, Johan, Skoog, Lambert, Yau, Christina, Benz, Christopher C, Esserman, Laura J, Stål, Olle, Nordenskjöld, Bo, Fornander, Tommy, Lindström, Linda S

“…To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. Secondary analysis of the Stockholm trial (STO-5,…”
Get full text

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer by Weiner, M., Skoog, L., Fornander, T., Nordenskjöld, B., Sgroi, D.C., Stål, O.

“…The oestrogen receptor (ER) co-activator amplified in breast cancer 1 (AIB1) has been suggested as a treatment predictive and prognostic marker in breast…”
Get full text

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer by Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle

“…Purpose The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after…”
Get full text